Biotechnology

Thursday Jan 19, 2023 - 10:54 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces $4.1M Registered Direct and Private Placement

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced its entry into a definitive agreement with investors for the purchase and sale of 4,315,786 shares in a registered direct offering. In a concurrent private placement, Jupiter Wellness also agreed to issue to the same investors a total of 8,631,572 warrants to purchase up to one share of common stock,…

Thursday Jan 19, 2023 - 10:00 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in InvestmentPitch Media Video Discussing Clinical Trial Application

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is front and center in a recent InvestmentPitch Media Video. The video spotlighted FDS Pharma’s recent submission of its clinical trial application for an upcoming phase a trial evaluating Lucid-MS. A candidate for treatment of multiple sclerosis…

Wednesday Jan 18, 2023 - 1:08 pm

InvestorNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Makes News in Finding Missing Woman

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, last week announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec, a location-awareness technology company. Expected to close on or before March 17, 2023, the acquisition will include TrakTec’s active paying subscriber base, police department contracts, commercial ready tracking products, and backend platform and mobile…

Wednesday Jan 18, 2023 - 10:06 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel (“Kernel”). The study was designed to evaluate Kernel’s Flow(R) wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The results from the feasibility study are very promising and provide further insights…

Tuesday Jan 17, 2023 - 10:11 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Among First of Nasdaq Companies to Dual List on Upstream

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, last week became the second NASDAQ company to dual list on Upstream under the ticker symbol JUPW. Jupiter Wellness released a digital collectible NFT to commemorate the dual listing, which is available for all Upstream participants to claim with the code “JUPW.” “We are thrilled to be among the first companies to…

Friday Jan 13, 2023 - 12:58 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently announced statistically significant (p<0.001) efficacy results in a preclinical in-vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “The study concluded that compared to pre-infection weight, the control group’s weight declined on average at 12.01%. In contrast,…

Friday Jan 13, 2023 - 11:55 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Authorized Share Repurchase Program

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced a share repurchase program. The company’s board of directors approved the repurchase under a normal course issuer bid; the bid is comprised of up to 1,925,210 of HUGE subordinate class B voting shares over the…

Friday Jan 13, 2023 - 9:45 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) CEO Reports on Company Accomplishments, Outlook through Shareholder Letter

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, is in an ideal position to be “profitable” in 2023. That was the outlook reported in a shareholder letter released by JUPW CEO Brian John. The letter noted 2022 highlights, such as the company becoming the second U.S. equity to dual list on Upstream, a revolutionary trading app for digital securities and…

Thursday Jan 12, 2023 - 12:39 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthracycline, Berubicin. The study, titled “Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas,” will be conducted at the Pomeranian…

Thursday Jan 12, 2023 - 10:42 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) CEO Featured in Traders News Source Interview

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, was featured in a new C-level interview with Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies. Branislav Vajdic, PhD, CEO and founder of HeartBeam joined Traders News Source’s Toni Loudenbeck…

Thursday Jan 12, 2023 - 9:49 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for CYB004 — its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule. “Based on preclinical data, CYB004 has shown promise in treating anxiety disorders. About half of people…

Wednesday Jan 11, 2023 - 12:04 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine

Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the GMP manufacturing of drug candidate ADI(TM)-100 for purposes of initiating…

Wednesday Jan 11, 2023 - 9:44 am

InvestorNewsBreaks — MetAlert Inc. (MLRT), TrakTec Sign Heads of Terms Agreement for Upcoming Acquisition

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, signed a Heads of Terms agreement with TrakTec outlining details about the previously announced acquisition. The agreement noted that MLRT would acquire the location-awareness technology company in a cash and stock deal worth $4.5 million. The agreement also notes that the acquisition should be closed on or before…

Tuesday Jan 10, 2023 - 1:41 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Featured on ‘Gametime with Sequire’

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, was featured in a recent interview with Sequire Spotlight. In the program, MetAlert’s CEO Patrick Bertagna joined Host Carmel Fisher to discuss the company’s business model and goals heading into the near future. “We’re a medical device/technologies company. We cater to a specific segment of the population…

Tuesday Jan 10, 2023 - 11:02 am

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the letter is from QSAM Biosciences executive chair and cofounder C. Richard Piazza and CEO and cofounder Douglas Baum. The letter noted that QSAM is developing its lead therapeutic radiopharmaceutical drug candidate,…

Tuesday Jan 10, 2023 - 10:20 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in…

Monday Jan 09, 2023 - 12:20 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of the most aggressive primary brain cancers. “The drug, Berubicin, is an anthracycline chemotherapy agent that apparently has the unique ability to cross the blood-brain…

Monday Jan 09, 2023 - 11:50 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The company also announced its expanded focus to investigate other products addressing acute medical needs due to substances of abuse such…

Monday Jan 09, 2023 - 10:03 am

InvestorNewsBreaks — MetAlert Inc. (MLRT) Featured in Ludlow Research Analyst Brief

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, spotlighted in a recent Q&A analyst report released by Ludlow Research. In the article, MLRT representations respond to questions, providing an overview of the company and discussing specific topics investors and shareholders might be interested in. The report delved into the company’s recent restructuring, name change and ticker…

Monday Jan 09, 2023 - 9:55 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a clinical trial. CYB003 is a deuterated psilocybin analog. CYBN anticipates…

Friday Jan 06, 2023 - 11:31 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that key executives will be attending the 41st annual J.P. Morgan Healthcare Conference. Scheduled for Jan. 9–12, 2023, in San Francisco, California, the conference has become largest and most informative healthcare investment symposium in the…

Friday Jan 06, 2023 - 9:56 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting additional results from a preclinical in vivo proof-of-concept study. The study evaluated BVXV’s innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy; results indicate that the presence of the SARS-COV-2 virus in the lungs of hamsters treated with BiondVax’s NanoAb…

Thursday Jan 05, 2023 - 12:38 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Receives Key Patent from European Patent Office

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has been issued a patent by the European Patent Office. The company received notification that the patent was issued covering the company’s flagship technology that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo(TM) credit card-sized device. This patent…

Thursday Jan 05, 2023 - 12:20 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the Virtual Investor 2023 “Companies to Watch” event. Climaco’s presentation is scheduled to take place beginning at 10 a.m. ET on Wednesday, Jan. 18,…

Thursday Jan 05, 2023 - 12:16 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Issues Shareholder Update

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today issued its year-end shareholder letter. In the update, the company’s CEO and Founder Patrick Bertagna shared insight on the company’s restructuring, branding and efforts to attract new investors and larger customers to execute its growth strategy, as well as the milestones that will shape MetAlert’s future.…

Thursday Jan 05, 2023 - 10:47 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Announces Participation in Upcoming Biotech Showcase

BiondVax Pharmaceuticals (NASDAQ: BVXV) CEO Amir Reichman will be presenting at the Biotech Showcase Conference, scheduled for Jan. 9–11, 2023. The conference is being held in San Francisco during the J.P. Morgan 41st annual Healthcare Conference. BiondVax board chair Mark Germain will also be available throughout the conference to meet with potential partners, collaborators and investors. BiondVax is a biotech company focused on developing, manufacturing…

Wednesday Jan 04, 2023 - 1:44 pm

InvestorNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Recaps 2022, Eyes 2023 as ‘Pivotal Year’

Universal Ibogaine (TSX.V: IBO) (“UI”), a life sciences company with a mission to transform the addiction treatment industry with medicalized ibogaine-centered care, today provided a year-end summary of 2022 accomplishments. “2022 was a busy year of behind-the-scenes activity laying the foundations with Health Canada in preparation for the planned clinical trial application and sourcing the related ibogaine drug supply,” said Nick Karos, chief executive officer…

Wednesday Jan 04, 2023 - 10:42 am

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Set to Begin IGC-AD1 Phase 2 Trials at Sites Throughout Canada

India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from Health Canada for approval of its “Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” The letter provides the acknowledgement of IGC-AD1’s drug candidacy and the authority to proceed with phase 2 trials in…

Tuesday Jan 03, 2023 - 2:33 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Strategic Board Appointment of Faith L. Charles, JD

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Faith L. Charles as chair of its board of directors. Since 2010, Charles has served as a corporate transactions and securities partner at the law firm of Thompson Hine, LLP. She currently leads the…

Tuesday Jan 03, 2023 - 1:06 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards submission of a clinical trial application (“CTA”) for its immunotherapeutic technology drug candidate, ADI(TM)-100. The CTA application will request approval for Adimune to conduct the first-in-human…

Thursday Dec 29, 2022 - 1:20 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market

BiondVax (NASDAQ: BVXV) is focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is developing a pipeline of nanosized antibody (‘NanoAb’) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, psoriasis, asthma, psoriatic arthritis, and wet macular degeneration. The company currently collaborates with the prestigious Max Planck Institute…

Thursday Dec 29, 2022 - 11:17 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Shareholder Letter, Including Corporate Update

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has issued a letter to shareholders. The letter, signed by HeartBeam CEO and founder Branislav Vajdic noted that 2022 was a “transformative” year for HeartBeam, highlighted by ongoing advancements in the company’s product launch timeline for the HeartBeam AIMIGo(TM) 12-Lead 3D…

Wednesday Dec 28, 2022 - 11:03 am

InvestorNewsBreaks – MetAlert Inc.’s (MLRT) RoomMate(TM) Delivers Efficiency, Privacy for Alzheimer’s, Dementia and ADA Patients

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, recently signed a letter of intent (“LOI”) with Sensio Group, a Norway-based provider of welfare technology and home automation solutions, for the marketing and distribution of RoomMate(TM). “RoomMate, one of MetAlert’s flagship products, is a wall-mounted alert system that delivers both efficiency and privacy. It detects and alerts caregivers about patient…

Thursday Dec 22, 2022 - 9:50 am

InvestorNewsBreaks – Aegis Capital Corp. Acted as Sole Bookrunner on BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) $8M Underwritten Public Offering

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Aegis Capital Corp., which is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions, acted as sole bookrunner on an $8 million underwritten public offering for BiondVax Pharmaceuticals. BiondVax…

Tuesday Dec 20, 2022 - 2:11 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Closes $8M Underwritten Public Offering

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the closing of its underwritten public offering with gross proceeds to the company to be $8,000,000. The offering consists of 1,600,000 units and pre-funded units, with each unit consisting of one American Depositary Share (“ADS”) and two warrants, each…

Tuesday Dec 20, 2022 - 11:26 am

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Files Updated Life Sciences Presentation

India Globalization Capital (NYSE American: IGC) today announced the filing of a life sciences presentation with the SEC on Form 8K. The presentation, available on the SEC website as well as published to IGC’s website, provides an overview of the company’s initiatives in life sciences. These include IGC’s focus on low-dose THC-based drug formulation and disease treatment and its various lines of cannabinoid-based consumer products.…

Tuesday Dec 20, 2022 - 11:04 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022. “2022 was a momentous year marked by steady progress across our pipeline of differentiated psychedelic-based therapeutics and partnerships targeting mental health. Most notable were the advancements of our two lead programs, CYB003 and CYB004, into clinical stage –…

Friday Dec 16, 2022 - 3:24 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Announces Launch of Game-Changing, Potentially Lifesaving GPS SmartSole in Canada

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, is a solution leader for consumers and patients with needs for remote monitoring. “MetAlert has announced that Canadian distributor Red Dot Alerts has launched the new award-winning 4G GPS SmartSole – a wearable medical monitoring device integrated into the orthotic insole allowing for discreet tracking and remote monitoring for those with…

Friday Dec 16, 2022 - 3:00 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Renowned Cardiologist to Help Define Best Paths to Advance Products

HeartBeam (NASDAQ: BEAT), a cardiac technology company, recently named a world-renowned interventional cardiologist with an impressive breadth of experience as its chief medical officer. “Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help HeartBeam continue to develop the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere… Dr. Fitzgerald joins HeartBeam after gaining invaluable experience in the clinical, research and industry sectors.…

Friday Dec 16, 2022 - 10:44 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raise $8M

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the pricing of its underwritten public offering. According to the announcement, the company anticipates gross proceeds from the offering, which consists of 1,600,000 units and prefunded units, to reach an estimated $8 million. The company specified that each unit…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions